1. Home
  2. TVRD vs RMR Comparison

TVRD vs RMR Comparison

Compare TVRD & RMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • RMR
  • Stock Information
  • Founded
  • TVRD 2017
  • RMR 1986
  • Country
  • TVRD United States
  • RMR United States
  • Employees
  • TVRD N/A
  • RMR N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • RMR Professional Services
  • Sector
  • TVRD Health Care
  • RMR Consumer Discretionary
  • Exchange
  • TVRD Nasdaq
  • RMR Nasdaq
  • Market Cap
  • TVRD 246.5M
  • RMR 290.8M
  • IPO Year
  • TVRD N/A
  • RMR N/A
  • Fundamental
  • Price
  • TVRD $33.88
  • RMR $17.05
  • Analyst Decision
  • TVRD Strong Buy
  • RMR
  • Analyst Count
  • TVRD 5
  • RMR 0
  • Target Price
  • TVRD $59.20
  • RMR N/A
  • AVG Volume (30 Days)
  • TVRD 22.1K
  • RMR 73.3K
  • Earning Date
  • TVRD 08-14-2025
  • RMR 11-10-2025
  • Dividend Yield
  • TVRD N/A
  • RMR 10.56%
  • EPS Growth
  • TVRD N/A
  • RMR N/A
  • EPS
  • TVRD N/A
  • RMR 1.12
  • Revenue
  • TVRD N/A
  • RMR $194,993,000.00
  • Revenue This Year
  • TVRD N/A
  • RMR $323.25
  • Revenue Next Year
  • TVRD N/A
  • RMR $1.07
  • P/E Ratio
  • TVRD N/A
  • RMR $15.17
  • Revenue Growth
  • TVRD N/A
  • RMR 1.73
  • 52 Week Low
  • TVRD $8.13
  • RMR $13.48
  • 52 Week High
  • TVRD $36.71
  • RMR $26.06
  • Technical
  • Relative Strength Index (RSI)
  • TVRD 66.16
  • RMR 55.45
  • Support Level
  • TVRD $29.33
  • RMR $16.64
  • Resistance Level
  • TVRD $31.88
  • RMR $17.10
  • Average True Range (ATR)
  • TVRD 2.09
  • RMR 0.30
  • MACD
  • TVRD 0.49
  • RMR 0.04
  • Stochastic Oscillator
  • TVRD 69.21
  • RMR 84.29

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About RMR The RMR Group Inc.

The RMR Group Inc is a holding company that conducts its business through its subsidiary, which is an alternative asset management company that invests in real estate and manages real estate-related businesses. Its business consists of providing management services to publicly owned real estate investment trusts, or REITs, and real estate-related operating companies. It also provides management services to real estate securities mutual funds and commercial real estate finance companies. The company's operating segment is RMR LLC and All Other Operations. The RMR Group derives its revenue from providing business and property management services as well as advisory and other services.

Share on Social Networks: